Rindopepimut: A promising immunotherapeutic for the treatment of glioblastoma multiforme

Immunotherapy

Volumn 6, Issue 6, 2014, Pages 679-690

  Swartz, Adam M ^a   Li, Qi Jing ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CDX 110; EGF receptor variant III; glioblastoma; glioma; immunotherapy; rindopepimut

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; KEYHOLE LIMPET HEMOCYANIN; RINDOPEPIMUT; TUMOR ANTIGEN; CANCER VACCINE; SUBUNIT VACCINE;

ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HUMAN; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CANCER VACCINES; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84904702260     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.21     Document Type: Review

References (73)

1. Agnihotri S, Burrell KE, Wolf A et al. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch. Immunol. Ther. Exp. (Warsz.) 61(1), 25-41 (2013).
2. Anton K, Baehring JM, Mayer T. Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol. Oncol. Clin. North Am. 26(4), 825-853 (2012).
3. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol. 18(1), 23-34 (2011).
4. Choi BD, Archer GE, Mitchell DA et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 19(4), 713-723 (2009).
5. Stiles CD, Rowitch DH. Glioma stem cells: a midterm exam. Neuron 58(6), 832-846 (2008).
6. McGirt MJ, Chaichana KL, Gathinji M et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J. Neurosurg. 110(1), 156-162 (2009).
7. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 331(2), 139-146 (2013).
8. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg. Focus. 20(4), E5 (2006).
9. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
10. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and beneft from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
11. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and effcacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 345(8956), 1008-1012 (1995).
12. Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel Wafers) in patients with primary malignant glioma. Neuro. Oncol. 5(2), 79-88 (2003).
13. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin Oncol. 27(28), 4733-4740 (2009).
14. Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin. Med. Insights Oncol. 5, 117-129 (2011).
15. Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin. Med. Insights Oncol. 7(123-135 (2013).
16. Kreisl TN, Zhang W, Odia Y et al. A Phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro. Oncol. 13(10), 1143-1150 (2011).
17. Weller M, Yung WK. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro. Oncol. 15(8), 971 (2013).
18. Kim YH, Jung TY, Jung S et al. Tumour-infltrating T-cell subpopulations in glioblastomas. Br. J. Neurosurg. 26(1), 21-27 (2012).
19. Yee C. Adoptive T cell therapy: addressing challenges in cancer immunotherapy. J. Transl. Med. 3(1), 17 (2005).
20. Sampson JH, Choi BD, Sanchez-Perez L et al. EGFRvIII mCAR-modifed T cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin. Cancer Res. 20(4), 972-984 (2014).
21. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832), 1107-1111 (2001).
22. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22(329-360 (2004).
23. Gill TJ 3rd, Lund RD. Implantation of tissue into the brain. An immunologic perspective. JAMA 261(18), 2674-2676 (1989).
24. Mason DW, Charlton HM, Jones AJ et al. The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. Neuroscience 19(3), 685-694 (1986).
25. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol. Rev. 213, 48-65 (2006).
26. Blaylock RL. Immunology primer for neurosurgeons and neurologists part 2: innate brain immunity. Surg. Neurol. Int. 4, 118 (2013).
27. Lafon M, Megret F, Lafage M, Prehaud C. The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J. Mol. Neurosci. 29(3), 185-194 (2006).
28. Lampron A, Elali A, Rivest S. Innate immunity in the CNS. redefning the relationship between the CNS and its environment. Neuron 78(2), 214-232 (2013).
29. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 33(12), 579-589 (2012).
30. Calzascia T, Masson F, Di Berardino-Besson W et al. Homing phenotypes of tumor-specifc CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity. 22(2), 175-184 (2005).
31. Carrithers MD, Visintin I, Kang SJ, Janeway CA Jr. Differential adhesion molecule requirements for immune surveillance and infammatory recruitment. Brain 123(Pt 6), 1092-1101 (2000).
32. Engelhardt B, Wolburg H. Mini-review: transendothelial migration of leukocytes: through the front door or around the side of the house? Eur. J. Immunol. 34(11), 2955-2963 (2004).
33. Bartholomaus I, Kawakami N, Odoardi F et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462(7269), 94-98 (2009).
34. Vajkoczy P, Laschinger M, Engelhardt B. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J. Clin. Invest. 108(4), 557-565 (2001).
35. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS infammation. Brain Pathol. 1(2), 97-105 (1991).
36. Agrawal S, Anderson P, Durbeej M et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203 (4), 1007-1019 (2006).
37. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
38. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
39. Bigner DD, Pitts OM, Wikstrand CJ. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J. Neurosurg. 55(1), 32-42 (1981).
40. Carter H, Chen S, Isik L et al. Cancer-specifc high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 69(16), 6660-6667 (2009).
41. Wong AJ, Bigner SH, Bigner DD et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplifcation. Proc. Natl Acad. Sci. USA 84(19), 6899-6903 (1987).
42. Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55(23), 5536-5539 (1995).
43. Frederick L, Eley G, Wang XY, James CD. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro. Oncol. 2(3), 159-163 (2000).
44. Wong AJ, Ruppert JM, Bigner SH et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl Acad. Sci. USA 89(7), 2965-2969 (1992).
45. Batra SK, Castelino-Prabhu S, Wikstrand CJ et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6(10), 1251-1259 (1995).
46. Boockvar JA, Kapitonov D, Kapoor G et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol. Cell. Neurosci. 24(4), 1116-1130 (2003).
47. Nagane M, Coufal F, Lin H et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56(21), 5079-5086 (1996).
48. Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother. Oncol. 72(3), 267-273 (2004).
49. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J. Biol. Chem. 275(23), 17358-17363 (2000).
50. Al-Nedawi K, Meehan B, Micallef J et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell. Biol. 10(5), 619-624 (2008).
51. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J. Neurovirol. 4(2), 148-158 (1998).
52. Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specifc and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55(14), 3140-3148 (1995).
53. Sampson JH, Crotty LE, Lee S et al. Unarmed, tumor-specifc monoclonal antibody effectively treats brain tumors. Proc. Natl Acad. Sci. USA 97(13), 7503-7508 (2000).
54. Ashley DM, Faiola B, Nair S et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186(7), 1177-1182 (1997).
55. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156(8), 2918-2926 (1996).
56. Heimberger AB, Archer GE, Crotty LE et al. Dendritic cells pulsed with a tumor-specifc peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50(1), 158-164; discussion 164-156 (2002).
57. Gilboa E, Lyerly HK, Vieweg J, Saito S. Immunotherapy of cancer using cytokine gene-modifed tumor vaccines. Semin. Cancer Biol. 5(6), 409-417 (1994).
58. + cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc. Natl Acad. Sci. USA 93(19), 10399-10404 (1996).
59. Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is effcacious against established intracerebral tumors. Clin. Cancer Res. 9(11), 4247-4254 (2003).
60. Sampson JH, Archer GE, Mitchell DA et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther. 8(10), 2773-2779 (2009).
61. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
62. +) T-cell responses to vaccine and is required for effcacy against brain tumors in mice. PLoS One 8(3), e59082 (2013).
63. Sampson JH, Aldape KD, Archer GE et al. Greater chemotherapy-induced lymphopenia enhances tumor-specifc immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro. Oncol. 13(3), 324-333 (2011).
64. Lai RK, Recht LD, Reardon DA et al. Long-term follow-up of ACT III: a Phase II trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma. Neurooncology 13(Suppl. 3), iii34-iii40 (2011).
65. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro. Oncol. 13(1), 3-13 (2011).
66. Monjazeb AM, Zamora AE, Grossenbacher SK et al. Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specifc therapies. Front. Oncol. 3, 197 (2013).
67. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol. 2011, 732413 (2011).
68. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71(6), 907-920 (2002).
69. Mehta AI, Persson O, Herndon JE II et al. Reply to M.S. Lesniak. J. Clin. Oncol. 29(22), 3105-3106 (2011).
70. + regulatory T cells in tumor-infltrating lymphocytes of human glioblastoma multiforme. Neuro. Oncol. 8(3), 234-243 (2006).
71. Yang I, Kremen TJ, Giovannone AJ et al. Modulation of major histocompatibility complex class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J. Neurosurg. 100(2), 310-319 (2004).
72. Wei J, Barr J, Kong LY et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 16(2), 461-473 (2010).
73. Kortylewski M, Kujawski M, Wang T et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11(12), 1314-1321 (2005).